PeptidePedia The community reference

Shenzhen Hybio Pharmaceutical (revision 12)

Old revision·13:04, 14 Oct 2025·EndotoxinEd

This is an old revision of this page, as it stood at 13:04, 14 Oct 2025, saved by EndotoxinEd with the summary fix a broken wikilink. It may differ substantially from the current revision, and any error it contains may since have been corrected.
This article is about the organisation. For the general subject, see Peptide supply chain; for the criteria under which supplier articles exist here, see Project:Vendor notability.
Shenzhen Hybio Pharmaceutical Co., Ltd.Organisation
representative synthesis and QC site (schematic)
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
Legal nameShenzhen Hybio Pharmaceutical Co., Ltd.
Trading nameHYB
Other designationsHybio, Hybio Pharmaceutical, 深圳翰宇药业股份有限公司
Identity
Founded2003
HeadquartersShenzhen, Guangdong, China
IndustryResearch-compound supply
Official siteVisit HYB at hybiopharmaceutical.com
Products and documentation
Product scopepeptide active pharmaceutical ingredients, contract manufacturing, research peptides and raw materials
Catalogue size350+ listings (self-reported)
DocumentationBatch certificate of analysis reported with orders
Independent reportsSubmitted to this wiki by purchasers; see §Independent testing record
Organisation infobox · conventions

Shenzhen Hybio Pharmaceutical Co., Ltd. (trading as HYB; hybiopharmaceutical.com) is a peptide active-ingredient manufacturer and contract development organisation trading as HYB from Shenzhen, Guangdong, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.[1][2]

The organisation is one of twenty-two covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]

Corporate identity and history

[edit]

Incorporated in Shenzhen in 2003, the organisation sits with the earlier incorporation dates among the entities covered on this wiki and predates the current research-peptide market by roughly a decade.[1] Shenzhen is inside the Pearl River Delta manufacturing belt, and the organisation's own material describes a business built on peptide active pharmaceutical ingredient supply and contract development rather than on catalogue distribution alone.[2]

The organisation describes itself as operating as a contract development and manufacturing organisation alongside its own listings. That is a self-published characterisation and is recorded here as one: nothing available to this wiki establishes the manufacturing arrangements behind it, and a registered business scope is a licensing fact rather than a capability finding.[2][1]

The documentary base is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic of the sector rather than of this entity.

Distribution and dispatch

[edit]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Operations and documentation practice

[edit]

Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot string on the certificate has corresponded to the vial label.[5] That correspondence is a minimum requirement rather than an achievement, and it is recorded only because traceability fails often enough elsewhere in this sector to make its absence the more common finding.

Water content by Karl Fischer titration appears on the certificates described in the submitted set more often than for most entities covered here, and peptide content is reported on a separate line from chromatographic purity across a substantial part of it.[5][6] Those two determinations are what let a purity percentage be read as a statement about mass, and their routine presence is the most useful documentary observation available about this organisation.

Product range

[edit]
ClassRepresentative listingsDocumentation reported
Peptide active ingredientsBulk peptide actives, protected fragmentsSpecification sheet with purity, water and content
Incretin analoguesSemaglutide, tirzepatide, retatrutideBatch certificate with HPLC trace and mass confirmation
Research peptidesBPC-157, TB-500, growth-hormone secretagoguesCertificate with purity, appearance and water
Custom synthesisSequences quoted individuallyCertificate with mass confirmation and stated analytical conditions
Raw materialsBulk powdersCertificate with purity; specification sheet on request

The active-ingredient listings are documented differently from the catalogue lines — a specification sheet rather than a single purity figure, and in places a reference to a drug master file said to be held with a regulator elsewhere. Whether such a file exists, and what it covers, is not established by any source available to this wiki, and a reader should treat the reference as a claim until it is.[2]

References

  1. ^ a b c National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
  2. ^ a b c d Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
  3. ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
  4. ^ PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
  5. ^ a b Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
  6. ^ United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.